Multiple prognostic tools help risk stratify older patients with multiple myeloma and predict treatment-specific survival, according to data that will be presented at the 22nd Congress of the European Hematology Association (June 22-25, 2017; Madrid, Spain).
-----
Related Content
Emerging and Novel Therapies in Multiple Myeloma
Best Therapy Combination for Multiple Myeloma
-----
SkylineDx—a commercial biotech company based in the Netherlands—announced the presentation of new data that validates the use of MMprofiler, a prognostic resource for risk-stratifying patients with multiple myeloma. The company also announced new data that demonstrates the value of the Treatment Outcome Prediction Using Similarity Between Patients (TOPSPIN) algorithm in predicting survival in patients with multiple myeloma who received a specific treatment.
MMprofiler, which assesses risk by measuring the activity of 92 multiple myeloma genes that comprise SKY92, was tested in a phase III clinical trial against the revised International Staging System. A total of 178 patients (median age, 73 years) were analyzed and followed for up to 34 months. MMprofiler identified 25 patients (14%) as high-risk. Researchers reported that the SHY92 classifier performed better than the revised International Staging System as a high-risk marker for overall survival.
MMprofiler will be available soon as a laboratory-developed test in the United States.
TOPSPIN, which identifies gene sets to predict if a patient is likely to survive longer when receiving a treatment of interest versus alternative treatments, was tested in a dataset involving 910 patients with multiple myeloma. Patients either received bortezomib (n = 407) or received an alternative therapy (n = 503). Researchers reported that TOPSPIN successfully identified subsets of patients with longer progression-frees survival when treated with bortezomib.
"Having already established proof of principle for MMprofiler and the TOPSPIN algorithm, we are gratified to have the utility of these prognostic tools further validated by the data presented at [European Hematology Association]," said Dharminder S Chahal, Chief Executive Officer, SkylineDx, in a press release (June 20, 2017). "We are confident that these datasets will enhance clinicians' understanding of the molecular factors that impact risk stratification and survival in patients with multiple myeloma, and that this knowledge will help improve the management of patients living with this devastating disease."—Zachary Bessette
